Neurocrine Biosciences (NBIX) Tops Q4 EPS by 30c
Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $1.05, $0.30 better than the analyst estimate of $0.75. Revenue for the quarter came in at $244.1 million versus the consensus estimate of $230.94 million.
Full-Year 2020 Financial Guidance | |||||||||||||||
Range | |||||||||||||||
(in millions) | Low | High | |||||||||||||
Combined GAAP R&D and SG&A expenses | $ | 740 | $ | 770 | |||||||||||
Combined Non-GAAP R&D and SG&A expenses | $ | 620 | $ | 650 | |||||||||||
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.